

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

If you are in any doubt about any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Beijing Chunlizhengda Medical Instruments Co., Ltd.\*** (北京市春立正達醫療器械股份有限公司), you should at once hand this circular together with the enclosed form of proxy to the purchaser or transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



**北京市春立正達醫療器械股份有限公司**  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

**EXTENSION OF THE VALIDITY PERIOD  
OF THE RESOLUTION CONCERNING THE A SHARE OFFERING  
AND THE AUTHORISATION CONCERNING THE A SHARE OFFERING  
AND  
NOTICES OF EGM AND CLASS MEETINGS**

The EGM, the Domestic Shareholders' Class Meeting and the H Shareholders' Class Meeting will be held at 9:30 a.m., 10:30 a.m. (or the time immediately after the conclusion of the EGM) and 11:00 a.m. (or the time immediately after the conclusion of the Domestic Shareholders' Class Meeting) respectively on Tuesday, 3 August 2021 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC. The forms of proxy for use at the EGM and the Class Meetings are enclosed and are also published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>). If you intend to appoint a proxy to attend the EGM and/or the Class Meetings, you are requested to complete and return the enclosed forms of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the EGM and/or the Class Meetings or any adjournment thereof (as the case may be). Completion and return of the forms of proxy will not preclude you from attending the EGM and/or the Class Meetings and voting in person if you so wish.

\* For identification purpose only

<b>CONTENTS</b>
-----------------

	<i>Page</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	4
<b>APPENDIX I – RESOLUTION CONCERNING THE A SHARE OFFERING</b> ..	10
<b>APPENDIX II – AUTHORIZATION CONCERNING THE A SHARE OFFERING</b> .....	13
<b>NOTICE OF THE EXTRAORDINARY GENERAL MEETING</b> .....	15
<b>NOTICE OF THE DOMESTIC SHAREHOLDERS’ CLASS MEETING</b> .....	17
<b>NOTICE OF THE H SHAREHOLDERS’ CLASS MEETING</b> .....	19

## DEFINITIONS

*In this circular, unless the context otherwise requires, the following terms shall have the following meanings:*

“A Share(s)”	means ordinary share(s) subscribed for in RMB, which are proposed to be issued by the Company under the A Share Offering;
“A Share Offering”	means the Company’s proposed initial public offering of no more than 38,428,000 A Shares, which will be listed on Shanghai Stock Exchange;
“Articles of Association”	means the articles of association of the Company (as amended from time to time);
“Authorization concerning the A Share Offering”	the granting of authorization by the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders’ class meeting and the 2020 second H Shareholders’ class meeting of the Company convened on 10 August 2020 to the Board and its authorized representatives to fully handle the specific matters in relation to the A Share Offering;
“Board” or “Board of Directors”	means the board of Directors;
“Class Meetings”	means the 2021 first class meeting for holders of Domestic Shares to be held immediately after the conclusion of the EGM, and the 2021 first class meeting for holders of H Shares to be held immediately after the conclusion of the said class meeting for holders of Domestic Shares, or any adjourned meeting thereof respectively;
“Company”	means Beijing Chunlizhengda Medical Instruments Co., Ltd.* (北京市春立正達醫療器械股份有限公司), a joint stock company incorporated in PRC with limited liability and the H Shares of which are listed and traded on the Main Board of the Stock Exchange (stock code: 1858);
“CSRC”	China Securities Regulatory Commission;
“Director(s)”	the director(s) of the Company;

## DEFINITIONS

“Domestic Share(s)”	ordinary shares of nominal value of RMB1.00 each in the share capital of the Company, which are subscribed for in RMB by Chinese citizens and/or entities incorporated in the PRC and are credited as fully paid up;
“Domestic Shareholder(s)”	holder(s) of Domestic Shares;
“Domestic Shareholders’ Class Meeting”	the 2021 first Domestic Shareholders’ class meeting of the Company to be held at 10:30 a.m. (or the time immediately after the conclusion of the EGM) on Tuesday, 3 August 2021;
“EGM” or “Extraordinary General Meeting”	the 2021 first extraordinary general meeting of the Company to be held at 9:30 a.m. on Tuesday, 3 August 2021 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC;
“Group”	the Company and its subsidiaries;
“H Share(s)”	overseas listed foreign shares with a nominal value of RMB1.00 each in the ordinary share capital of the Company, which are listed on the main board of the Stock Exchange;
“H Shareholder(s)”	the holder(s) of H Shares;
“H Shareholders’ Class Meeting”	the 2021 first H Shareholders’ class meeting of the Company to be held at 11:00 a.m. (or the time immediately after the conclusion of the Domestic Shareholders’ Class Meeting) on Tuesday, 3 August 2021;
“Hong Kong”	the Hong Kong Special Administrative Region of PRC;
“Latest Practicable Date”	13 July 2021, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained in this circular;
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange;

## DEFINITIONS

“PRC” or “China”	the People’s Republic of China which, for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan;
“Resolution concerning the A Share Offering”	the resolution by the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders’ class meeting and the 2020 second H Shareholders’ class meeting of the Company convened on 10 August 2020 concerning the A Share Offering;
“RMB”	Renminbi, the lawful currency of PRC;
“Share(s)”	the Domestic Share(s) and/or the H Share(s);
“Shareholder(s)”	means the holder(s) of the Shares;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited; and
“%”	per cent.

Words importing the singular shall, where applicable, include the plural and vice versa. Words importing the masculine gender shall, where applicable, include the feminine and neuter genders. References to persons shall, where applicable, include corporations.

Any reference in this circular to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any word defined under the Listing Rules, the Securities and Futures Ordinance or any modification thereof and used in this circular shall, where applicable, have the meaning assigned to it under the Listing Rules, the Securities and Futures Ordinance or any modification thereof, as the case may be.

If there is any inconsistency between the English and Chinese versions of this circular, the English version shall prevail unless otherwise stated.

\* *For identification purpose only*

LETTER FROM THE BOARD



北京市春立正達醫療器械股份有限公司  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

*Executive Directors*

Mr. Shi Chunbao

Ms. Yue Shujun

Mr. Xie Feng Bao

*Non-Executive Directors*

Mr. Wang Xin

*Independent Non-Executive Directors*

Mr. Ge Changyin

Mr. Weng Jie

Mr. Wong Tak Shing

*Registered office and Headquarters  
in PRC*

No.10 Xinmi Xi Er Road  
Southern District of Tongzhou  
Economic Development Zone  
Tongzhou District

Beijing  
PRC

Postal Code: 101112

*Principal Place of Business in Hong Kong*

20th Floor, Winbase Centre  
208 Queen's Road Central  
Sheung Wan  
Hong Kong

*To the Shareholders*

Dear Sir or Madam,

**EXTENSION OF THE VALIDITY PERIOD OF  
THE RESOLUTION CONCERNING THE A SHARE OFFERING  
AND THE AUTHORISATION CONCERNING THE A SHARE OFFERING  
AND  
NOTICES OF EGM AND CLASS MEETINGS**

**1. INTRODUCTION**

References are made to the announcements of the Company dated 3 November 2015, 22 April 2020 and 5 June 2020 and the circular of the Company dated 24 July 2020 in relation to, among others, the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering. Reference is further made to the announcement of the Company dated 7 July 2021 in relation to the proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering.

## LETTER FROM THE BOARD

On 7 July 2021, the Board approved and resolved to submit to the EGM and Class Meetings (as the case may be) for approval of the following resolution in relation to the A Share Offering:

### SPECIAL RESOLUTION

1. Proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering.

The purpose of this circular is to provide you with relevant information to enable you to make informed decision on whether to vote for or against the above resolution to be proposed at the EGM and the Class Meetings (as the case may be).

### 2. PROPOSED EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTION CONCERNING THE A SHARE OFFERING AND THE AUTHORIZATION CONCERNING THE A SHARE OFFERING

The Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering were approved at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020. The validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering were 12 months from the date on which they were considered and approved at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company.

As of the Latest Practicable Date, given that the A Share Offering is still in progress and the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering will expire on 9 August 2021, it is reasonable to propose to extend the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering for 12 months in consideration of the progress of the registration and the validity period of the registration approval. The Board proposes to extend the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering for 12 months from the next day immediately after the expiration of validity period (i.e., ending on 9 August 2022) for the purpose of ensuring the on-going proceeding of the A Share Offering.

The resolution in relation to the proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering will be submitted by way of a special resolution at the EGM and the Class Meetings for consideration and approval. Save for above, all other contents in respect of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering will remain unchanged. For more details, please refer to the Appendix I to II in this circular.

## LETTER FROM THE BOARD

### 3. OTHER INFORMATION FOR THE A SHARE OFFERING

#### 3.1. Benefits of and reasons for the A Share Offering

The Company has set out reasons and benefits for the A Share Offering in its circular dated 24 July 2020, which includes that the Directors consider that the A Share Offering will enhance the corporate image of the Company, further broaden the Company's funding channels and increase the Company's working capital and recognitions of capital market by attracting large institutional and medium and small investors. The Directors also believe that the A Share Offering will be beneficial to the Company's business growth, financing flexibility and business development, and be beneficial to obtain more financial resources and improve the competitiveness of the Company, and be beneficial to the long term development of the Company.

Taking into account these reasons and benefits, the Company is of the view that the proposed extensions of 12 months of the Resolution concerning the A Share Offering and the Authorisation concerning the A Share Offering are necessary and reasonable so as to enable the Company to proceed with the A Share Offering at such time when the Company considers appropriate, and are in the interests of the Company and the Shareholders as a whole.

#### 3.2. Effects of the A Share Offering on shareholding structure of the Company

Assuming that a total of 38,428,000 A Shares are permitted to be issued under the A Share Offering and the issued share capital of the Company remains unchanged prior to completion of the A Share Offering, the shareholding structure of the Company as at the Latest Practicable Date and immediately after the completion of the A Share Offering is set out as follows:

	As at the Latest Practicable Date		Immediately after completion of the A Share Offering (assuming the over-allotment option is not exercised)		Immediately after completion of the A Share Offering (assuming the over-allotment option is fully exercised)	
	Number of Shares	Approximate percentage of the issued share capital of the Company	Number of Shares	Approximate percentage of the issued share capital of the Company	Number of Shares	Approximate percentage of the issued share capital of the Company
<b>Non-public Shareholders</b>						
Domestic Shares	250,000,000	72.3%	-	-	-	-
A Shares to be converted from Domestic Shares in issue	-	-	250,000,000	65.1%	250,000,000	64.1%
<b>Public Shareholders</b>						
A Shares proposed to be issued under the A Share Offering	-	-	38,428,000	10.0%	44,192,200	11.3%
H Shares	95,852,000	27.2%	95,852,000	24.9%	95,852,000	24.6%
<b>Total</b>	<b>345,852,000</b>	<b>100%</b>	<b>384,280,000</b>	<b>100%</b>	<b>390,044,200</b>	<b>100%</b>



## LETTER FROM THE BOARD

As at the Latest Practicable Date, based on the publicly available information and to the Directors' knowledge, all the H Shares are held by the public and the Company has maintained a public float above 25% which satisfies the requirements under the Listing Rules. Assuming that all 38,428,000 A Shares under the A Share Offering are issued upon approval and that all are issued to non-connected persons of the Company, the percentage of the H Shares held by the public in the total number of Shares after the issuance is expected to be approximately 24.9%, and the percentage of the Shares (total of A Shares and H Shares) held by the public in the total number of the Shares after issuance is expected to be approximately 34.9%. The Company's public float will still be able to comply with the requirements of Rule 8.08 of the Listing Rules. The Company will closely monitor its public float to ensure its compliance, at all times, with relevant public float requirements.

As at the Latest Practicable Date, the Company has not entered into or intends to enter into any agreement with any connected persons of the Company in connection with subscription of A Shares.

### 3.3. Progress of A Share Offering

On 5 June 2020, the Board resolved to approve relevant proposals of the Company on the A Share Offering. The relevant proposals in relation to the A Share Offering were considered and approved at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020. On 22 December 2020, the Company received a notice of acceptance issued by the Shanghai Stock Exchange to the Company and a copy of the prospectus of the A Share Offering (the "A Share Prospectus") has been published on the website of the Review and Approval of the Issuance of Listing of Stocks on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (上海證券交易所科創板股票發行上市審核網站) at [kcb.sse.com.cn](http://kcb.sse.com.cn) for preliminary publication.

As at the Latest Practicable Date, the A Share Offering has progressed to the stage of responding to questions raised by the Shanghai Stock Exchange. The expected timeline for the A Share Offering is as below:

- The Shanghai Stock Exchange will raise questions to the Company by way of inquiry letter and the Company will then provide written responses accordingly (the "Q&A"). The length of time of the Q&A would depend on the number of questions the Shanghai Stock Exchange may have and whether the Company can properly address their concerns. The Q&A is estimated to be completed before the year end of 2021.
- Upon completion of the Q&A, the Shanghai Stock Exchange will arrange a review meeting (the "Meeting") with its listing committee (the "Listing Committee"). The Company and representatives from the sponsor will attend the Meeting and response to the Listing Committee.

## LETTER FROM THE BOARD

- After the Meeting and upon the approval by the Listing Committee, the Shanghai Stock Exchange will submit an application to the CSRC for registration of the Shares.
- Upon the completion of the registration of the Shares in the CSRC, the Company will arrange for the issuance of the A Shares. The major tasks of the issuance of the A Shares include performing road show, determining strategic allotment if needed, offline placement and online subscription, determining whether or not to adopt overallotment option, etc., after which the process of the issuance of the A Shares will be completed.
- The Company will then determine the listing date of the A Shares. The existing Domestic Shares in issue of the Company will be converted into A Shares on the listing date of the A Shares.

The expected timeline for the A Share Offering above is based on the best estimation of the Company. It will be subject to change based on the current and future market conditions and development of the Company.

#### 4. THE EGM AND CLASS MEETINGS

Notices convening the EGM, the Domestic Shareholders' Class Meeting and the H Shareholders' Class Meeting to be held at 9:30 a.m., 10:30 a.m. (or the time immediately after the conclusion of the EGM) and 11:00 a.m. (or the time immediately after the conclusion of the Domestic Shareholders' Class Meeting) respectively on Tuesday, 3 August 2021 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou, District, Beijing, the PRC, respectively, are set out on pages 15 to 20 to this circular and their respective proxy forms are also enclosed hereto.

In order to be qualified to attend and vote at the EGM and H Shareholder Class Meetings, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong by no later than 4:30 p.m. on Friday, 30 July 2021.

Shareholders whose names appear on the Company's register of members at the close of business on Friday, 30 July 2021 are entitled to attend and vote at the EGM and/or the Class Meetings.

The forms of proxy for use at the EGM and the Class Meetings are also enclosed. Such forms of proxy are also published on the websites of Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.clzd.com>). If you intend to attend the EGM and/or the Class Meetings by proxy, you are requested to complete and return the enclosed proxy form(s) in accordance with the instructions printed thereon and deposit the form not less than 24 hours before the time appointed for the holding of the EGM and/or the Class Meetings or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM and/or the Class Meetings if you so wish.

## LETTER FROM THE BOARD

Under the Listing Rules, no Shareholders are required to abstain from voting at the EGM and the Class Meetings respectively.

### 5. PROCEDURES FOR VOTING AT THE EGM AND CLASS MEETINGS

According to Rule 13.39(4) of the Hong Kong Listing Rules, the vote of Shareholders at the EGM and/or the Class Meetings will be taken by poll. Accordingly, all the resolution could be taken by poll at the EGM and/or the Class Meetings pursuant to the Articles of Association.

### 6. RECOMMENDATION

The Directors believe that the resolution mentioned above are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that Shareholders vote in favour of the resolution to be proposed at the EGM and/or the Class Meetings as set out in the notice of the EGM and/or the Class Meetings.

### 7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,  
By Order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
**Shi Chunbao**  
*Chairman*

Beijing, the PRC  
16 July, 2021

\* *for identification purpose only*

Resolution concerning the A Share Offering was considered and approved at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020. Details of A Share Offering are as follows:

**1. CLASS OF SHARES**

Shares to be issued are domestic listed ordinary shares denominated in RMB (A Shares).

**2. NOMINAL VALUE PER A SHARE**

RMB1.00

**3. NUMBER OF A SHARES TO BE ISSUED**

The number of A Shares proposed to be issued will not exceed 38,428,000 A Shares, representing no more than 10% of the total share capital of the Company upon the completion of the issuance. The Company and the lead underwriter can exercise the over-allotment option and the number of Shares to be over-allocated shall not exceed 15% of the size of the A Share Offering. The specific number of A Shares to be issued will be determined by the Board based on the authorization granted at the EGM and the Class Meetings and the negotiation with lead underwriters based on specific circumstances and the final number of total issued A Shares shall be subject to the limit approved by the CSRC. All of the Shares to be issued are new Shares and does not involve the transfer of existing Shares.

**4. PRICING METHODOLOGY**

The issue price will be determined by making enquiries with offline investors, or by the Company and the lead underwriter(s) after negotiation, or by such other methods as permitted by the CSRC and other relevant regulatory authorities.

When determining the issue price of the A Shares, the Company will take into consideration the following factors: (i) the operational and financial conditions of the Company; (ii) the prevailing market conditions; (iii) the market demand for the A Shares; (iv) the industry which the Company operates in; (v) the requirements under the applicable laws and regulations; and (vi) the average price-to-earnings ratio of other A share listed issuer(s) who operate in the same industry which the Company operates in.

Based on the company law of the PRC, the issue price of the A Shares shall not be lower than the nominal value of the Shares of the Company, i.e. RMB1.00 per Share. There are no other legal or regulatory requirements stipulating the price floor in the A Share Offering. The Company does not intend to issue the A Shares at a price lower than the latest audited net asset value per share prior to the A Share Offering.

**5.      METHOD OF ISSUE**

The A Share Offering will be conducted by a combination of offline placement and online subscription, or such other method(s) of issue as permitted by the CSRC and other relevant regulatory authorities, with reference to market conditions and other relevant factors.

Online subscription is a public subscription through the online trading system of the Shanghai Stock Exchange. Any individual or institution holding a securities trading account can participate in such online subscription via (i) telephone; (ii) self-service terminal; or (iii) online.

**6.      TARGET OF SUBSCRIBERS**

Investors who are in compliance with the requirements under PRC laws, regulations and regulatory documents.

According to Article 11 of the Initial Public Offering Shares Issuance Placement Rules (《首次公開發行股票配售細則》) of the PRC, the Company and its underwriters are prohibited from allocating the A Shares in its initial offering to certain parties, including but not limited to, (i) the Company, its shareholders, actual controllers, Directors, supervisors, and senior management, and any companies which any of them has direct and indirect actual control, joint control or in which they have material influence and the controlling shareholders of such companies, its subsidiaries or any other subsidiaries that such companies control, and other employees of the Company; (ii) close family members of the natural persons in (i), including spouses, children and their spouses, parents and parents-in-law, brothers, sisters and their spouses, brothers-in-law and sisters-in-law, parents of sons-in-law and daughters-in-law, for their subscription. The Company and its underwriter(s) shall strictly follow all applicable PRC laws and regulations in allocating the A Shares to potential subscribers under the A Share Offering.

Furthermore, prior to the issuance of A Shares, the Company will provide a list of related parties (as defined under the relevant listing rules of the Shanghai Stock Exchange) of the Company and all connected persons (as defined under Chapter 14A of the Listing Rules) of the Company to its sponsor to the A Share Offering. Its sponsor will then review the list and submit the list to the Shanghai Stock Exchange and the underwriter(s) to the A Share Offering. All persons listed on this list, including the related parties (as defined under the listing rules of the Shanghai Stock Exchange) and connected persons (as defined under Chapter 14A of the Listing Rules) of the Company will not be permitted to subscribe for any A Shares in the A Share Offering. The Directors believe that such measures can ensure no A Shares under the A Share Offering will be allocated to and subscribed by the connected persons of the Company (as defined under Chapter 14A of the Listing Rules).

**7.      FORM OF UNDERWRITING**

The A Share Offering will be underwritten by the lead underwriter(s) on a standby commitment basis.

**8.      PLACE OF LISTING**

Shanghai Stock Exchange.

**9.      VALID PERIOD OF THE RESOLUTION**

The validity period of the resolution for A Share Offering will be extended 12 months from 9 August 2021 after it is considered and approved at the EGM, the H Shareholders' Class Meeting and the Domestic Shareholders' Class Meeting (i.e., ending on 9 August 2022).

If the Company fails to complete the A Share Offering within the extended validity period of the resolution and intends to continually proceed with the A Share Offering, the Company shall seek further approval at a general meeting, H shareholders' class meeting and Domestic Shareholders' class meeting for the A Share Offering.

Upon the completion of the A Share Offering, the Company will apply for the conversion into a joint stock company with limited liability with domestic and overseas listed shares. The Domestic Shares in issue will be converted into A Shares upon the completion of A Share Offering. Further, the A Share Offering will be made pursuant to the specific mandate approved at the 2020 second extraordinary general meeting, the 2020 second class meetings for holders of Domestic Share and the 2020 second class meeting for holders of H Shares.

## APPENDIX II AUTHORIZATION CONCERNING THE A SHARE OFFERING

Authorization concerning the A Share Offering was considered and approved at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020. The details of the proposal are set out as below:

To fully handle the Company's application for the A Share Offering and specific matters at the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020, respectively. The content and scope of the authorization include, but are not limited to:

- (a) in accordance with the laws, regulations, relevant regulatory requirements of the CSRC, Shanghai Stock Exchange and other relevant regulatory authorities and the resolution approved by the 2020 second extraordinary general meeting, the 2020 second Domestic Shareholders' class meeting and the 2020 second H Shareholders' class meeting of the Company convened on 10 August 2020, to determine, adjust and implement, in collaboration with the sponsor (lead underwriter(s)), the detailed proposal on the A Share Offering (including but not limited to the timing of the A Share Offering, the final number of A Shares to be issued, the final issue price and methods of issue, etc.);
- (b) to appoint the relevant intermediaries and determine their professional fees;
- (c) to determine the stock exchange and sector of listing by taking into account the actual situation of the Company and after consulting with the relevant authorities;
- (d) to prepare, sign, deliver and amend the documents and to sign material contracts relating to the A Share Offering in accordance with relevant laws, regulations and requirement of relevant regulatory departments;
- (e) to make appropriate adjustments to specific arrangements of the use of proceeds and investment projects in accordance with relevant laws, regulations and the requirement of the government competent authorities;
- (f) upon the approval of the CSRC in respect of the A Share Offering and its listing, to revise the relevant provisions of the Articles of Association in accordance with the actual circumstances of the A Shares Offering;
- (g) to handle matters in relation to the initial registration of the A Shares, the listing and circulation of the A Shares on the Shanghai Stock Exchange, the circulation of lock-up matters and other related matters after the completion of the A Share Offering;
- (h) to handle matters relating to the registration filing in relation to the A Share Offering; and
- (i) to handle other matters relating to the A Share Offering and the listing of the A Shares.

## APPENDIX II AUTHORIZATION CONCERNING THE A SHARE OFFERING

The validity period of the authorization will be extended for 12 months, from the date on which the proposal is considered and approved at the EGM, the H Shareholders' Class Meeting and the Domestic Shareholders' Class Meeting by way of a special resolution (i.e., ending on 9 August 2022). If the Company fails to complete the A Share Offering within the extended validity period of the resolution and intends to continually proceed with the A Share Offering, the Company shall seek further approval at a general meeting, H shareholders' class meeting and Domestic Shareholders' class meeting for the A Share Offering.

Upon the completion of the A Share Offering, the Company will apply for the conversion into a joint stock company with limited liability with domestic and overseas listed shares. The Domestic Shares in issue will be converted into A Shares upon the completion of A Share Offering. Further, the A Share Offering will be made pursuant to the specific mandate approved at the 2020 second extraordinary general meeting, the 2020 second class meetings for holders of Domestic Share and the 2020 second class meeting for holders of H Shares.



NOTICE OF THE EXTRAORDINARY GENERAL MEETING



北京市春立正達醫療器械股份有限公司  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

**Notice is hereby given** that the extraordinary general meeting (the "EGM") of Beijing Chunlizhengda Medical Instruments Co., Ltd. (the "Company") will be held at 9:30 a.m. on Tuesday, 3 August 2021 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC to consider and, if thought fit, to pass the following resolution:

**SPECIAL RESOLUTION**

1. To consider and approve the proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering.

By order of the Board

**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

**Shi Chunbao**

*Chairman*

Beijing, the PRC

16 July 2021

\* *For identification purpose only*

\*\* *Unless otherwise stated, the capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 16 July 2021.*

*As at the date of this notice, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.*

# NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Notes:

## 1. REGISTRATION OF MEMBERS

In order to be qualified to attend and vote at the EGM, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong by no later than 4:30 p.m. on Friday, 30 July 2021.

Shareholders whose names appear on the Company's register of members at the close of business on Friday, 30 July 2021 are entitled to attend and vote at the EGM.

## 2. APPOINTMENT OF PROXY

Any Shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the Shareholder or of his/her attorney duly authorised in writing or, if the Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong (for holders of H Shares) or the registered office of the Company at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou, Economic Development Zone, Tongzhou District, Beijing, the PRC (for holders of Domestic Shares), not less than 24 hours before the time appointed for holding the EGM or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude Shareholders from attending and voting in person at the EGM.

## 3. CONTACT PERSON OF THE COMPANY

Contact Person: Mr. Shi Chunsheng  
Contact Tel: (8610) 5861 1761/62/63  
Contact Fax: (8610) 5861 1751

## 4. PROCEDURES OF VOTING AT EGM

Pursuant to Rule 13.39(4) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, any vote of Shareholders at the EGM must be taken by poll.

## 5. OTHERS

The EGM is expected to take half a day. Shareholders attending the EGM (in person or by proxy) are responsible for their own transportation and accommodation fees. Identification documents must be shown by shareholder(s) or proxies to attend the EGM.

NOTICE OF THE DOMESTIC SHAREHOLDERS' CLASS MEETING



北京市春立正達醫療器械股份有限公司  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

NOTICE OF THE DOMESTIC SHAREHOLDERS' CLASS MEETING

Notice is hereby given that a class meeting of the holders of domestic shares (the "Domestic Shareholders' Class Meeting") of Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the "Company") will be held at 10:30 a.m. (or the time immediately after the conclusion of the EGM) on Tuesday, 3 August 2021 or any adjournment thereof at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC, to consider and, if thought fit, to pass the following resolution:

SPECIAL RESOLUTION

1. To consider and approve the proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering.

By order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
**Shi Chunbao**  
*Chairman*

Beijing, the PRC  
16 July 2021

\* For identification purpose only

\*\* Unless otherwise stated, the capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 16 July 2021.

*As at the date of this notice, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.*

# NOTICE OF THE DOMESTIC SHAREHOLDERS' CLASS MEETING

Notes:

## 1. REGISTRATION OF MEMBERS

Domestic Shareholders whose names appear on the Company's register of members at the close of business on Friday, 30 July 2021 are entitled to attend and vote at the Domestic Shareholders' Class Meeting.

## 2. APPOINTMENT OF PROXY

Any Domestic Shareholder entitled to attend and vote at the Domestic Shareholders' Class Meeting is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a Domestic Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the Domestic Shareholder or of his/her attorney duly authorised in writing or, if the Domestic Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the Domestic Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to registered office of the Company at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou, Economic Development Zone, Tongzhou District, Beijing, the PRC, not less than 24 hours before the time appointed for holding the Domestic Shareholders' Class Meeting or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude Domestic Shareholders from attending and voting in person at the Domestic Shareholders' Class Meeting.

## 3. CONTACT PERSON OF THE COMPANY

Contact Person: Mr. Shi Chunsheng  
Contact Tel: (8610) 5861 1761/62/63  
Contact Fax: (8610) 5861 1751

## 4. PROCEDURES OF VOTING AT THE DOMESTIC SHAREHOLDERS' CLASS MEETING

A Domestic Shareholder or his/her/its proxy may exercise the right to vote by poll.

## 5. OTHERS

The Domestic Shareholders' Class Meeting is expected to take place immediately after the EGM. Domestic Shareholders attending the Domestic Shareholders' Class Meeting (in person or by proxy) are responsible for their own transportation and accommodation fees.

Identification documents must be shown by shareholder(s) or proxies to attend the Domestic Shareholders' Class Meeting.

## NOTICE OF THE H SHAREHOLDERS' CLASS MEETING



### 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

## NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

Notice is hereby given that a class meeting of the holders of H shares (the "H Shareholders' Class Meeting") of Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the "Company") will be held at 11:00 a.m. (or the time immediately after the conclusion of the Domestic Shareholders' Class Meeting) on Tuesday, 3 August 2021 or any adjournment thereof at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC, to consider and, if thought fit, to pass the following resolution:

### SPECIAL RESOLUTION

1. To consider and approve the proposed extension of the validity period of the Resolution concerning the A Share Offering and the Authorization concerning the A Share Offering.

By order of the Board  
Beijing Chunlizhengda Medical Instruments Co., Ltd.\*  
**Shi Chunbao**  
Chairman

Beijing, the PRC  
16 July 2021

\* For identification purpose only

\*\* Unless otherwise stated, the capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 16 July 2021.

As at the date of this notice, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

# NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

Notes:

## 1. REGISTRATION OF MEMBERS

In order to be qualified to attend and vote at the H Shareholders' Class Meeting, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong by no later than 4:30 p.m. on Friday, 30 July 2021.

H Shareholders whose names appear on the Company's register of members at the close of business on Friday, 30 July 2021 are entitled to attend and vote at the H Shareholders' Class Meeting.

## 2. APPOINTMENT OF PROXY

Any H Shareholder entitled to attend and vote at the H Shareholders' Class Meeting is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a H Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the H Shareholder or of his/her attorney duly authorised in writing or, if the H Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the H Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not less than 24 hours before the time appointed for holding the H Shareholders' Class Meeting or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude H Shareholders from attending and voting in person at the H Shareholders' Class Meeting.

## 3. CONTACT PERSON OF THE COMPANY

Contact Person:	Mr. Shi Chunsheng
Contact Tel:	(8610) 5861 1761/62/63
Contact Fax:	(8610) 5861 1751

## 4. PROCEDURES OF VOTING AT THE H SHAREHOLDERS' CLASS MEETING

An H Shareholder or his/her/its proxy may exercise the right to vote by poll.

## 5. OTHERS

The H Shareholders' Class Meeting is expected to take place immediately after the Domestic Shareholders' Class Meeting. H Shareholders attending the H Shareholders' Class Meeting (in person or by proxy) are responsible for their own transportation and accommodation fees.

Identification documents must be shown by shareholder(s) or proxies to attend the H Shareholders' Class Meeting.